Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

by Giuseppe Saglio, Dong Wook Kim, Surapol Issaragrisil, Philipp Le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil Gallagher, Albert Hoenekopp, Mei Dong, Ariful Haque, Richard A. Larson, Hagop M. Kantarjian
Published 2018

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021),...

by Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus
Published 2022

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

by Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus
Published 2022